← All Sponsors
SPONSOR

Guangzhou Lupeng Pharmaceutical Company LTD.

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Diffuse Large B-Cell Lymphoma (DLBCL)
NCT07189065 Phase 2
Recruiting

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
China View Trial →